Inhaled chemotherapy in lung cancer: Future concept of nanomedicine

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1551-1572

  Zarogoulidis, Paul ^a   Chatzaki, Ekaterini ^b   Porpodis, Konstantinos ^a   Domvri, Kalliopi ^a   Hohenforst Schmidt, Wolfgang ^c   Goldberg, Eugene P ^d   Karamanos, Nikos ^e   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d University of Florida   (United States)

^e UNIVERSITY OF PATRAS   (Greece)

Author keywords

Carriers; Inhaled chemotherapy; Transducers

Indexed keywords

ABC TRANSPORTER; CARBOHYDRATE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; ORGANIC CATION TRANSPORTER; PACLITAXEL; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; POLYMER; RUBITECAN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DRUG CARRIER;

BRONCHITIS; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; COUGHING; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EPIGLOTTITIS; FATIGUE; FUNCTIONAL ANATOMY; HOARSENESS; HUMAN; HYPOXIA; IONIC STRENGTH; LUNG CANCER; LUNG CIRCULATION; LUNG CLEARANCE; LUNG HEMORRHAGE; LUNG STRUCTURE; METERED DOSE INHALER; NAUSEA; NEBULIZER; NEUROTOXICITY; NONHUMAN; PARTICLE SIZE; PH; PHARYNGITIS; POWDER INHALER; REVIEW; SORE THROAT; THORAX PAIN; TUMOR VOLUME; VOMITING; WHEEZING; CHEMISTRY; HISTOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG TUMOR; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALIA;

ADMINISTRATION, INHALATION; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LIPOSOMES; LUNG; LUNG NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEBULIZERS AND VAPORIZERS;

EID: 84865760040     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29997     Document Type: Review

References (255)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911 J Clin Oncol. 2007;25(30):4800-4805.
3. Curran WJ Jr, Schiller JH, Wolkin AC, Comis RL. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer. 2008;9(4):222-226.
4. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer. 2008;9(2):102-105.
5. Novello S, Longo M, Levra MG. Toward therapies tailored to patient characteristics. J Thorac Oncol. 2007;2(Suppl 5):S38-S41.
6. Subramanian J, Waqar SN, Govindan R. Targeted therapy in lung cancer: lessons learned from past experiences. J Thorac Oncol. 2011; 6(11 Suppl 4):S1786-S1788.
7. Garcia Sar D, Aguado L, Montes Bayon M, et al. Relationships between cisplatin-induced adducts and DNA strand-breaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair. Mutat Res. 2012;741(1-2):81-88.
8. Hosomi Y, Shibuya M, Niho S, et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res. 2011;31(10):3449-3456.
9. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2(12):1067-1077.
10. Hunter TB, Manimala NJ, Luddy KA, Catlin T, Antonia SJ. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res. 2011;31(10):3193-3204.
11. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
12. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8):583-592.
13. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395-1403.
14. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
15. Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs. 2004;22(1):27-37.
16. Robinson WR, Coberly C, Beyer J, Lewis A, Ballard C. Office-based intraperitoneal chemotherapy for ovarian cancer. J Oncol Pract. 2008; 4(5):225-228.
17. Hofstra LS, Bos AM, de Vries EG, et al. A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer. 2001;85(11):1627-1633.
18. Osaki T, Hanagiri T, Nakanishi R, Yoshino I, Taga S, Yasumoto K. Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study. Chest. 1999;115(5):1424-1428.
19. Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J. 2002;23(20):1625-1631.
20. Markman M, Cleary S, Pfeifle C, Howell SB. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer. 1986;58(1):18-21.
21. Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol. 1991;9(2):313-319.
22. Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol. 2002;54(2): 159-180.
23. Duvillard C, Romanet P, Cosmidis A, Beaudouin N, Chauffert B. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann Otol Rhinol Laryngol. 2004; 113(3 Pt 1):229-233.
24. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588-599.
25. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care. 2005;50(9):1161-1176.
26. Bakker EM, Volpi S, Salonini E, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J. 2011;38(6):1328-1335.
27. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 2011;38(5): 1071-1080.
28. Yu KN, Minai-Tehrani A, Chang SH, et al. Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS One. 2010;5(12):e15623.
29. Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E. Inhaled insulin: too soon to be forgotten? J Aerosol Med Pulm Drug Deliv. 2011;24(5):213-223.
30. Zarogoulidis P, Eleftheriadou E, Sapardanis I, et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs. July 8, 2011. [Epub ahead of print.]
31. Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S. New chemotherapeutic method for the treatment of tracheal and bronchial cancers-nebulization chemotherapy. Gan No Rinsho. 1983;29(7): 765-770. Japanese.
32. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer. 1993;68(6):1146-1149.
33. Gautam A, Koshkina N. Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets. 2003;3(4):287-296.
34. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res. 1999;5(9):2653-2659.
35. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med. 2004;17(1):7-14.
36. Minchin RF, Johnston MR, Aiken MA, Boyd MR. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Exp Ther. 1984;229(1):193-198.
37. Otterson GA, Villalona-Calero MA, Hicks W, et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2466-2473.
38. Gavini E, Manunta L, Giua S, Achenza G, Giunchedi P. Spray-dried poly(D, L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies. AAPS Pharm Sci Tech. 2005;6(1):E108-E114.
39. Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets. 2003;3(4):265-273.
40. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv. 2008;21(1):61-70.
41. Selting K, Waldrep JC, Reinero C, et al. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv. 2008;21(3):255-268.
42. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med. 2006;19(3):385-391.
43. Gagnadoux F, Pape AL, Lemarie E, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26(4): 657-661.
44. Chao P, Deshmukh M, Kutscher HL, et al. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs. 2010;21(1):65-76.
45. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials. 2009;30(20): 3476-3485.
46. Schaffer MW, Roy SS, Mukherjee S, Ong DE, Das SK. Uptake of all-trans retinoic acid-containing aerosol by inhalation to lungs in a guinea pig model system-a pilot study. Exp Lung Res. 2010;36(10):593-601.
47. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release. 2011;150(1):49-55.
48. Hureaux J, Lagarce F, Gagnadoux F, et al. Lipid nanocapsules: readyto-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm. 2009;73(2):239-246.
49. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med (Maywood). 2004;229(11):1169-1176.
50. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001;7(10):3258-3262.
51. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A. 2010;107(23):10737-10742.
52. Otterson GA, Villalona-Calero MA, Sharma S, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007;13(4):1246-1252.
53. Wittgen BP, Kunst PW, van der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 2007;13(8):2414-2421.
54. Wattenberg LW, Wiedmann TS, Estensen RD. Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res. 2004;64(7):2347-2349.
55. Knight V, Koshkina NV, Golunski E, Roberts LE, Gilbert BE. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. Trans Am Clin Climatol Assoc. 2004;115:395-404.
56. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004;10(7):2319-2326.
57. Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol. 2004;54(5):421-431.
58. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009; 26(7):1752-1763.
59. Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006;319(1-2):155-161.
60. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipidcoated nanoparticles. J Pharm Sci. 2006;95(6):1196-1211.
61. Rodriguez CO Jr, Crabbs TA, Wilson DW, et al. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2010;23(4):197-206.
62. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005;116(3):458-463.
63. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol. 1999;44(3):187-192.
64. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol. 2001;19(6):1839-1847.
65. Swift DL. Aerosols and humidity therapy. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis. 1980; 122(5 Pt 2):71-77.
66. Phipps PR, Gonda I, Anderson SD, Bailey D, Bautovich G. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Eur Respir J. 1994;7(8):1474-1482.
67. Shinohara H. Distribution of lymphatic stomata on the pleural surface of the thoracic cavity and the surface topography of the pleural mesothelium in the golden hamster. Anat Rec. 1997;249(1):16-23.
68. Lai-Fook SJ. Mechanical factors in lung liquid distribution. Annu Rev Physiol. 1993;55:155-179.
69. Nunn JF. Nunn's Applied Respiratory Physiology. 4th ed. Oxford, UK: Butterworth-Heineman; 1993.
70. Deffebach ME, Charan NB, Lakshminarayan S, Butler J. The bronchial circulation. Small, but a vital attribute of the lung. Am Rev Respir Dis. 1987;135(2):463-481.
71. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J. 1999;13(5):1177-1188.
72. Summers QA. Inhaled drugs and the lung. Clin Exp Allergy. 1991;21(3): 259-268.
73. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD. Allometric relationships of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol. 1992;6(2):235-243.
74. Folkesson HG, Matthay MA, Westrom BR, Kim KJ, Karlsson BW, Hastings RH. Alveolar epithelial clearance of protein. J Appl Physiol. 1996;80(5):1431-1445.
75. Martonen TB. Mathematical model for the selective deposition of inhaled pharmaceuticals. J Pharm Sci. 1993;82(12):1191-1199.
76. Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care. 2000;45(6):652-666.
77. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987;136(6): 1445-1449.
78. Messina MS, Smaldone GC. Evaluation of quantitative aerosol techniques for use in bronchoprovocation studies. J Allergy Clin Immunol. 1985;75(2):252-257.
79. Dolovich MB, Killian D, Wolff RK, Obminski G, Newhouse MT. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am Rev Respir Dis. 1977; 115(3):397-402.
80. Dolovich MB, Sanchis J, Rossman C, Newhouse MT. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol. 1976;40(3):468-471.
81. Davis JN, Stagg D. Interrelationships of the volume and time components of individual breaths in resting man. J Physiol. 1975;245(2): 481-498.
82. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol. 2001;47(5):451-456.
83. Stegen K, Neujens A, Crombez G, Hermans D, Van de Woestijne KP, Van den Bergh O. Negative affect, respiratory reactivity, and somatic complaints in a CO2 enriched air inhalation paradigm. Biol Psychol. 1998;49(1-2):109-122.
84. Kleinstreuer C, Zhang Z, Li Z. Modeling airflow and particle transport/ deposition in pulmonary airways. Respir Physiol Neurobiol. 2008;163(1-3):128-138.
85. Zhang Z, Kleinstreuer C, Kim CS. Airflow and nanoparticle deposition in a 16-generation tracheobronchial airway model. Ann Biomed Eng. 2008;36(12):2095-2110.
86. Crank J. The Mathematics of Diffusion. 2nd ed. Oxford, UK: Clarendon Press; 1975.
87. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324-4327.
88. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2(4):266-276.
89. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 1997;26(2-3):71-90.
90. Milosevic MF, Fyles AW, Wong R, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer. 1998;82(12):2418-2426.
91. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10): 806-813.
92. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1): 58-65.
93. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039-3051.
94. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol. 1997;23(4):249-260.
95. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis. 1984; 129(2):211-215.
96. Jonas DE, Wines RCM, DelMonte M, et al. Drug Class Review: Controller Medications for Asthma: Final Update 1 Report. Portland, OR: Oregon Health & Science University; 2011.
97. Dolovich MB, Ramsdale EH. Replacing CFC aerosols with powders. CMAJ. 1990;142(10):1036.
98. Newman SP. Therapeutic inhalation agents and devices. Effectiveness in asthma and bronchitis. Postgrad Med. 1984;76(5):194-203.
99. Bennett WD, Smaldone GC. Human variation in the peripheral airspace deposition of inhaled particles. J Appl Physiol. 1987;62(4): 1603-1610.
100. Dolovich M, Ryan G, Newhouse MT. Aerosol penetration into the lung; influence on airway responses. Chest. 1981;80(Suppl 6):834-836.
101. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl. 1982;119:101-104.
102. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981; 36(1):52-55.
103. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl. 1982;119:57-65.
104. Pavia D, Thomson ML, Clarke SW, Shannon HS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax. 1977;32(2):194-197.
105. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46(10):712-716.
106. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest. 1993;104(5):1332-1337.
107. Dolovich M. Rationale for spacer use in children. Pediatr Pulmonol Suppl. 1997;16:184-185.
108. Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med. 1996;90(2):69-77.
109. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med. 1999;12 Suppl 1:S9-S17.
110. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J. 1989;2(3): 247-252.
111. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003; 56(6):600-612.
112. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7(1):69-73.
113. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med. Summer 1993;6(2): 99-110.
114. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med. 2003; 97(2):181-187.
115. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593-604.
116. Amani A, York P, Chrystyn H, Clark BJ, Do DQ. Determination of factors controlling the particle size in nanoemulsions using artificial neural networks. Eur J Pharm Sci. 2008;35(1-2):42-51.
117. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
118. Kendrick AH, Smith EC, Wilson RS. Selecting and using nebuliser equipment. Thorax. 1997;52 Suppl 2:S92-S101.
119. Boe J, Dennis JH, O'Driscoll BR, et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18(1):228-242.
120. Smith EC, Denyer J, Kendrick AH. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J. 1995;8(7):1214-1221.
121. Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003;22(2):263-267.
122. Niven RW, Ip AY, Mittelman S, Prestrelski SJ, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res. 1995;12(1):53-59.
123. Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J Liposome Res. 2006;16(2):113-125.
124. Elhissi AM, Karnam KK, Danesh-Azari MR, Gill HS, Taylor KM. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J Pharm Pharmacol. 2006;58(7):887-894.
125. Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharm Res. 2007;24(2):277-287.
126. Johnson JC, Waldrep JC, Guo J, Dhand R. Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. Respir Care. 2008;53(12):1703-1708.
127. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med. 2005;18(3):354-363.
128. Harris KW, Smaldone GC. Facial and ocular deposition of nebulized budesonide: effects of face mask design. Chest. 2008;133(2):482-488.
129. Smaldone GC, Sangwan S, Shah A. Facemask design, facial deposition, and delivered dose of nebulized aerosols. J Aerosol Med. 2007;20 Suppl 1:S66-S75.
130. Erzinger S, Schueepp KG, Brooks-Wildhaber J, Devadason SG, Wildhaber JH. Facemasks and aerosol delivery in vivo. J Aerosol Med. 2007;20 Suppl 1:S78-S83.
131. Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng. 2008;10: 195-220.
132. Dunne A, O'Hara T, Devane J. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. Stat Med. 1999;18(14):1865-1876.
133. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12 Suppl 1:S19-S24.
134. Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable handheld multidose nebulizer. J Pharm Sci. 1996;85(9):960-964.
135. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998; 113(4):957-963.
136. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460-1472.
137. Storm G, Crommelin DJ. Colloidal systems for tumor targeting. Hybridoma. 1997;16(1):119-125.
138. Suarez S, Gonzalez-Rothi RJ, Schreier H, Hochhaus G. Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res. 1998;15(3):461-465.
139. Fielding RM, Abra RM. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm Res. 1992;9(2):220-223.
140. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 2005;7(1):E20-E41.
141. Gonzalez-Rothi RJ, Suarez S, Hochhaus G, et al. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res. 1996; 13(11):1699-1703.
142. Gonzalez-Rothi RJ, Straub L, Cacace JL, Schreier H. Liposomes and pulmonary alveolar macrophages: functional and morphologic interactions. Exp Lung Res. 1991;17(4):687-705.
143. Lasic DD. Liposomes in Gene Delivery. Boca Raton, FL: CRC Press;1997.
144. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs. 1998;56(5):747-756.
145. Schreier H, Gagne L, Bock T, et al. Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes. Pharm Acta Helv. 1997;72(4):215-223.
146. Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm Res. 1990;7(11):1127-1133.
147. Desai TR, Hancock RE, Finlay WH. A facile method of delivery of liposomes by nebulization. J Control Release. 2002;84(1-2):69-78.
148. Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res. 1991;8(2):217-221.
149. Niven RW, Carvajal TM, Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm Res. 1992;9(4):515-520.
150. Joshi M, Misra A. Dry powder inhalation of liposomal ketotifen fumarate: formulation and characterization. Int J Pharm. 2001;223(1-2): 15-27.
151. Skalko-Basnet N, Pavelic Z, Becirevic-Lacan M. Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev Ind Pharm. 2000;26(12):1279-1284.
152. Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagace J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994; 38(5):1090-1095.
153. Woodle MC, Collins LR, Sponsler E, Kossovsky N, Papahadjopoulos D, Martin FJ. Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophys J. 1992;61(4): 902-910.
154. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta. 1997;1334(2-3):161-172.
155. Hutchinson FG, Furr BJ. Biodegradable polymers for controlled release of peptides and proteins. Horiz Biochem Biophys. 1989;9:111-129.
156. Ehrhardt C, Fiegel J, Fuchs S, et al. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J Aerosol Med. 2002;15(2):131-139.
157. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62(1-2):279-287.
158. Cheng YS, Yazzie D, Gao J, Muggli D, Etter J, Rosenthal GJ. Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. J Aerosol Med. 2003;16(1):65-73.
159. Dhiman N, Khuller GK. Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol. 1998;21(1):19-28.
160. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release. 1998;51(2-3):143-152.
161. Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res. 2003;20(5): 788-796.
162. Bittner B, Kissel T. Ultrasonic atomization for spray drying: a versatile technique for the preparation of protein loaded biodegradable microspheres. J Microencapsul. 1999;16(3):325-341.
163. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev. 2001; 47(1):39-54.
164. Langer R. Drug delivery and targeting. Nature. 1998;392(Suppl 6679): 5-10.
165. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002;99(19):12001-12005.
166. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868-1871.
167. Cannon GJ, Swanson JA. The macrophage capacity for phagocytosis. J Cell Sci. 1992;101(Pt 4):907-913.
168. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm. 2004;270(1-2):297-306.
169. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res. 1996;13(1):80-83.
170. Winters MA, Knutson BL, Debenedetti PG, et al. Precipitation of proteins in supercritical carbon dioxide. J Pharm Sci. 1996;85(6):586-594.
171. Sellers SP, Clark GS, Sievers RE, Carpenter JF. Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization. J Pharm Sci. 2001;90(6):785-797.
172. Hickey WA. Factors influencing the distortion of sex ratio in Aedes aegypti. J Med Entomol. 1970;7(6):727-735.
173. Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC. Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res. 1999;16(2): 249-254.
174. Klink DT, Chao S, Glick MC, Scanlin TF. Nuclear translocation of lactosylated poly-L-lysine/cDNA complex in cystic fibrosis airway epithelial cells. Mol Ther. 2001;3(6):831-841.
175. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm Res. 1998;15(11): 1748-1752.
176. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2 In vivo drug delivery. J Pharm Sci. 1996;85(11):1142-1169.
177. Woodle MC, Scaria P, Ganesh S, et al. Sterically stabilized polyplex: ligand-mediated activity. J Control Release. 2001;74(1-3):309-311.
178. Klonne DR, Dodd DE, Losco PE, Troup CM, Tyler TR. Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. Drug Chem Toxicol. 1989;12(1):39-48.
179. Zhang L, Zhu W, Song L, et al. Effects of hydroxylpropyl-betacyclodextrin on in vitro insulin stability. Int J Mol Sci. 2009;10(5): 2031-2040.
180. Bruck A, Abu-Dahab R, Borchard G, Schafer UF, Lehr CM. Lectin-functionalized liposomes for pulmonary drug delivery: interaction with human alveolar epithelial cells. J Drug Target. 2001;9(4):241-251.
181. Abu-Dahab R, Schafer UF, Lehr CM. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J Pharm Sci. 2001;14(1):37-46.
182. Yi SM, Harson RE, Zabner J, Welsh MJ. Lectin binding and endocytosis at the apical surface of human airway epithelia. Gene Ther. 2001;8(24):1826-1832.
183. Kloss A, Henklein P, Siele D, et al. The cell-penetrating peptide octaarginine is a potent inhibitor of proteasome activities. Eur J Pharm Biopharm. 2009;72(1):219-225.
184. Strayer MS, Guttentag SH, Ballard PL. Targeting type II and Clara cells for adenovirus-mediated gene transfer using the surfactant protein B promoter. Am J Respir Cell Mol Biol. 1998;18(1):1-11.
185. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 2000; 6(5):1949-1957.
186. Cristiano RJ, Roth JA. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther. 1996;3(1):4-10.
187. Lundberg M, Wikstrom S, Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol Ther. 2003;8(1):143-150.
188. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 1996;271(30): 18188-18193.
189. Kurten RC. Sorting motifs in receptor trafficking. Adv Drug Deliv Rev. 2003;55(11):1405-1419.
190. Hasegawa S, Hirashima N, Nakanishi M. Microtubule involvement in the intracellular dynamics for gene transfection mediated by cationic liposomes. Gene Ther. 2001;8(21):1669-1673.
191. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216-237.
192. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105-127.
193. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm. 2006;3(1):62-69.
194. Lechapt-Zalcman E, Hurbain I, Lacave R, et al. MDR1-Pgp 170 expression in human bronchus. Eur Respir J. 1997;10(8):1837-1843.
195. Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol. 2002; 55(5):332-339.
196. van der Valk P, van Kalken CK, Ketelaars H, et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990;1(1):56-64.
197. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38(9):1277-1287.
198. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3-29.
199. Hsia TC, Lin CC, Wang JJ, Ho ST, Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung. 2002;180(3): 173-179.
200. Lallemand JY, Stoven V, Annereau JP, et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet. 1997;350(9079):711-712.
201. Naumann N, Siratska O, Gahr M, Rosen-Wolff A. P-glycoprotein expression increases ATP release in respiratory cystic fibrosis cells. J Cyst Fibros. 2005;4(3):157-168.
202. Ye S, MacEachran DP, Hamilton JW, O'Toole GA, Stanton BA. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am J Physiol Cell Physiol. 2008;295(3):C807-C818.
203. van der Deen M, Marks H, Willemse BW, et al. Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch. 2006;449(6):682-688.
204. Blokzijl H, Vander Borght S, Bok LI, et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis. 2007;13(6): 710-720.
205. Henriksson G, Norlander T, Zheng X, Stierna P, Westrin KM. Expression of P-glycoprotein 170 in nasal mucosa may be increased with topical steroids. Am J Rhinol. 1997;11(4):317-321.
206. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999;442(2-3):208-214.
207. Dinis-Oliveira RJ, Duarte JA, Remiao F, Sanchez-Navarro A, Bastos ML, Carvalho F. Single high dose dexamethasone treatment decreases the pathological score and increases the survival rate of paraquat-intoxicated rats. Toxicology. 2006;227(1-2):73-85.
208. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031-2035.
209. Langmann T, Mauerer R, Zahn A, et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem. 2003;49(2): 230-238.
210. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57(16):3537-3547.
211. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996;148(4): 1237-1247.
212. Brechot JM, Hurbain I, Fajac A, Daty N, Bernaudin JF. Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem Cytochem. 1998;46(4):513-517.
213. van der Deen M, de Vries EG, Visserman H, et al. Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. J Biochem Mol Toxicol. 2007;21(5):243-251.
214. van der Deen M, Homan S, Timmer-Bosscha H, et al. Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells. Int J Chron Obstruct Pulmon Dis. 2008;3(3):469-475.
215. Bleasby K, Castle JC, Roberts CJ, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica. 2006; 36(10-11):963-988.
216. Horvath G, Mendes ES, Schmid N, et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J Allergy Clin Immunol. 2007;120(5):1103-1109.
217. Lips KS, Volk C, Schmitt BM, et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005;33(1):79-88.
218. Horvath G, Schmid N, Fragoso MA, et al. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol. 2007;36(1):53-60.
219. Kummer W, Lips KS, Pfeil U. The epithelial cholinergic system of the airways. Histochem Cell Biol. 2008;130(2):219-234.
220. Kummer W, Wiegand S, Akinci S, et al. Role of acetylcholine and muscarinic receptors in serotonin-induced bronchoconstriction in the mouse. J Mol Neurosci. 2006;30(1-2):67-68.
221. Groneberg DA, Fischer A, Chung KF, Daniel H. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am J Respir Cell Mol Biol. 2004;30(3):251-260.
222. Sondergaard HB, Brodin B, Nielsen CU. hPEPT1 is responsible for uptake and transport of Gly-Sar in the human bronchial airway epithelial cell-line Calu-3. Pflugers Arch. 2008;456(3):611-622.
223. Groneberg DA, Eynott PR, Doring F, et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax. 2002;57(1):55-60.
224. Endter S, Francombe D, Ehrhardt C, Gumbleton M. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol. 2009;61(5):583-591.
225. Saito H, Terada T, Okuda M, Sasaki S, Inui K. Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochim Biophys Acta. 1996;1280(2):173-177.
226. Bosquillon C. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci. 2010;99(5): 2240-2255.
227. Miyazaki H, Sekine T, Endou H. The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol Sci. 2004;25(12):654-662.
228. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica. 2008; 38(7-8):778-801.
229. Adachi H, Suzuki T, Abe M, et al. Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003;285(6):F1188-F1197.
230. Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci. 2006; 95(5):1127-1143.
231. Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci. 2006;95(5): 1114-1126.
232. Liang HF, Chen CT, Chen SC, et al. Paclitaxel-loaded poly(gammaglutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials. 2006;27(9): 2051-2059.
233. Musumeci T, Vicari L, Ventura CA, Gulisano M, Pignatello R, Puglisi G. Lyoprotected nanosphere formulations for paclitaxel controlled delivery. J Nanosci Nanotechnol. 2006;6(9-10):3118-3125.
234. Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux JC. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res. 2006;23(4):752-758.
235. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007;2(4):415-423.
236. Aggarwal AN, Agarwal R. The new ATS/ERS guidelines for assessing the spirometric severity of restrictive lung disease differ from previous standards. Respirology. 2007;12(5):759-762.
237. Kreider ME, Grippi MA. Impact of the new ATS/ERS pulmonary function test interpretation guidelines. Respir Med. 2007;101(11): 2336-2342.
238. Lawson KA, Anderson K, Menchaca M, et al. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther. 2003;2(5):437-444.
239. Knight V. Anticancer effect of an alpha-TEA liposome aerosol. Exp Biol Med (Maywood). 2005;230(5):291.
240. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol. 1999; 44(3):177-186.
241. Gagnadoux F, Leblond V, Vecellio L, et al. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol. 2006;58(2): 237-244.
242. Gagnadoux F, Le Pape A, Urban T, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005;18(2):198-206.
243. Lemarie E, Vecellio L, Hureaux J, et al. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv. 2011;24(6):261-270.
244. Min R, Li T, Du J, Zhang Y, Guo J, Lu WL. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. Can J Physiol Pharmacol. 2008;86(5): 288-298.
245. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004;91 Suppl 2:S18-S23.
246. Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer. 2004;91 Suppl 2:S1-S2.
247. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4): 301-326.
248. Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol. 1997;8(2): 191-194.
249. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80(2): 286-291.
250. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for nonsmall cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs. 2003;14(8):665-668.
251. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 2003;63(16):5054-5059.
252. Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm. 2008;357(1-2):286-294.
253. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res. 2004;64(17):6214-6224.
254. Pakunlu RI, Cook TJ, Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res. 2003;20(3):351-359.
255. Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 2006;114(2): 153-162.